CommercialPrior AuthMedium impact
Pharmacy Program Updates: Prior Authorization Changes Effective June 15, 2026
BCBS Illinois·IL · Neurology, Cardiology, Gastroenterology +4 more·Prior Authorization
Effective date
Jul 1, 2026
We identified it
Jun 16, 2026
Summary
Blue Cross Blue Shield of Illinois is updating prior authorization criteria for multiple pharmacy programs effective July 1, 2026, including new programs for Aqvesme and Voyxact, and criteria updates for medications treating conditions like migraine, amyloidosis, and immunomodulators. These changes affect members with prescription drug benefits administered by Prime Therapeutics across various plan types.
Action Required
By July 1, 2026: Clinical staff must review updated prior authorization criteria for affected pharmacy programs including Acute Migraine, Aqvesme, ATTR Amyloidosis, Biologic Immunomodulators, Constipation Agents, Continuous Glucose Monitor, IL-4 Inhibitors, Otezla, Tezspire, and Vijoice medications. Update prescribing workflows to ensure compliance with new PA requirements. Note that some programs (Interstitial Lung Disease and TPO-RA) have earlier effective date of April 15, 2026, and Voyxact becomes effective August 1, 2026. Failure to obtain required prior authorization may result in coverage denials.